meningococcal group A, B, C, W and Y vaccine

MenABCWY (GSK3536852A) is an investigational pentavalent meningococcal vaccine developed by GSK (originally by Novartis Vaccines and Diagnostics) to prevent invasive meningococcal disease (IMD). The vaccine is a combination of the antigenic components of two established vaccines: Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal Groups A, C, Y, and W-135 Oligosaccharide Conjugate Vaccine). It contains four components targeting serogroup B (recombinant proteins fHbp, NadA, and NHBA, plus outer membrane vesicles) and four conjugate components targeting serogroups A, C, W-135, and Y (capsular polysaccharides conjugated to the CRM197 carrier protein). By providing coverage against the five most common serogroups in a single product, the vaccine aims to simplify immunization schedules and improve compliance among adolescents and young adults, who are at higher risk for meningococcal disease.

Brand names

Bexserca

Other names

MenABCYW-135 vaccineMenABCYW135 vaccineMenABCYW 135 vaccineMenABCWY vaccineMenB+MenACWY combination vaccinepentavalent meningococcal vaccine